Dessika Rahmawati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dessika Rahmawati has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dwita Sukmala Ratih1 shared publication
- Eko Arisetijono
Department of Neurology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
1 shared publication - Fatma Rahmalia Izzati
Dr. Saiful Anwar General Hospital, Malang, East Java, Indonesia
1 shared publication M. Biomed
1 shared publication- Shahdevi Nandar Kurniawan
Department of Neurology, Faculty of Medicine, University of Brawijaya, Malang, Indonesia
1 shared publication - Sri Andarini
Brawijaya University
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Brawijaya University in MNJ (Malang Neurology Journal)
- Vol. 12 (2) , 126-132
DEVELOPMENT SCORING SYSTEM TO PREDICT IN-HOSPITAL MORTALITY IN STROKE PATIENTS IN INDONESIA
Background: Stroke is the third leading cause of death globally, and early prediction of in-hospital mortality risk is essential for improving clinical outcomes and optimizing resource allocation. However, no in-hospital mortality system applicable to both ischemic and hemorrhagic stroke currently exists in Indonesia. This study aims to identify significant predictors of in-hospital mortality among stroke patients, to develop an in-hospital mortality prediction score system, and to assess the performance of the score. Methods: This retrospective cohort study included stroke patients hospitalized at Dr. Saiful Anwar Hospital, Malang, Indonesia in January-December 2024, with data obtained from electronic medical records. Multivariate logistic regression with backward stepwise elimination was performed to identify predictors significantly associated with in-hospital mortality. Scoring weights were derived from regression coefficients. Model performance was assessed using accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the curve (AUC). Results: Eight significant predictors were identified: age ≥60 years, male sex, National Institute of Health Stroke Scale (NIHSS) ≥16, leukocytosis, hyperglycemia, hemorrhagic stroke type, pneumonia, and sepsis. These predictors were incorporated into an in-hospital mortality scoring system. The scoring system demonstrated an accuracy of 72.92%, sensitivity 80%, specificity 71.77%, PPV 31.37%, NPV 95.7%, and an AUC of 0.784. Conclusions: Eight out of thirteen proposed predictors were significantly associated with in-hospital mortality among stroke patients. Based on these predictors, a prognostic scoring system for in-hospital mortality was developed, demonstrating fair discriminative performance.
- 20 May 2026
- Published by Brawijaya University in MNJ (Malang Neurology Journal)
- Vol. 12 (2) , 126-132
Open AccessDEVELOPMENT SCORING SYSTEM TO PREDICT IN-HOSPITAL MORTALITY IN STROKE PATIENTS IN INDONESIA
Background: Stroke is the third leading cause of death globally, and early prediction of in-hospital mortality risk is essential for improving clinical outcomes and optimizing resource allocation. However, no in-hospital mortality system applicable to both ischemic and hemorrhagic stroke currently exists in Indonesia. This study aims to identify significant predictors of in-hospital mortality among stroke patients, to develop an in-hospital mortality prediction score system, and to assess the performance of the score. Methods: This retrospective cohort study included stroke patients hospitalized at Dr. Saiful Anwar Hospital, Malang, Indonesia in January-December 2024, with data obtained from electronic medical records. Multivariate logistic regression with backward stepwise elimination was performed to identify predictors significantly associated with in-hospital mortality. Scoring weights were derived from regression coefficients. Model performance was assessed using accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the curve (AUC). Results: Eight significant predictors were identified: age ≥60 years, male sex, National Institute of Health Stroke Scale (NIHSS) ≥16, leukocytosis, hyperglycemia, hemorrhagic stroke type, pneumonia, and sepsis. These predictors were incorporated into an in-hospital mortality scoring system. The scoring system demonstrated an accuracy of 72.92%, sensitivity 80%, specificity 71.77%, PPV 31.37%, NPV 95.7%, and an AUC of 0.784. Conclusions: Eight out of thirteen proposed predictors were significantly associated with in-hospital mortality among stroke patients. Based on these predictors, a prognostic scoring system for in-hospital mortality was developed, demonstrating fair discriminative performance.
- Open Access
- 31 March 2026
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 17 (1) , 67-75
Relationship Between Dexamethasone Therapy and Sleep Quality, Insomnia, and Melatonin Levels in Patients With Brain Tumors
Background and Objective Dexamethasone is a corticosteroid commonly used in patients with brain tumors to manage vasogenic edema and intracranial pressure. However, it is often associated with sleep disturbances that can impair patients’ quality of life. This study aimed to evaluate the relationship between dexamethasone therapy and sleep disorders using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and serum melatonin levels in patients with brain tumors.Methods A cross-sectional study was conducted involving 66 patients with brain tumors at Saiful Anwar General Hospital, Malang. Subjects were divided into two groups: dexamethasone users and non-users. Sleep quality was assessed using PSQI and ISI, while melatonin levels were analyzed from blood samples drawn during daytime (11:00–12:00 am).Results The dexamethasone group had significantly higher PSQI (p=0.006) and ISI (p<0.001) scores, indicating worse sleep quality and greater insomnia severity compared to non-users. However, there was no significant association between melatonin levels and dexamethasone use (p=0.131).Conclusions Dexamethasone therapy is associated with impaired sleep quality and increased insomnia severity in brain tumor patients. However, no significant correlation was found between melatonin levels and sleep disturbances. The daytime sampling of melatonin may have limited the hormonal assessment. Further studies with nocturnal sampling are recommended.
- 31 March 2026
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 17 (1) , 67-75
Open AccessRelationship Between Dexamethasone Therapy and Sleep Quality, Insomnia, and Melatonin Levels in Patients With Brain Tumors
Background and Objective Dexamethasone is a corticosteroid commonly used in patients with brain tumors to manage vasogenic edema and intracranial pressure. However, it is often associated with sleep disturbances that can impair patients’ quality of life. This study aimed to evaluate the relationship between dexamethasone therapy and sleep disorders using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and serum melatonin levels in patients with brain tumors.Methods A cross-sectional study was conducted involving 66 patients with brain tumors at Saiful Anwar General Hospital, Malang. Subjects were divided into two groups: dexamethasone users and non-users. Sleep quality was assessed using PSQI and ISI, while melatonin levels were analyzed from blood samples drawn during daytime (11:00–12:00 am).Results The dexamethasone group had significantly higher PSQI (p=0.006) and ISI (p<0.001) scores, indicating worse sleep quality and greater insomnia severity compared to non-users. However, there was no significant association between melatonin levels and dexamethasone use (p=0.131).Conclusions Dexamethasone therapy is associated with impaired sleep quality and increased insomnia severity in brain tumor patients. However, no significant correlation was found between melatonin levels and sleep disturbances. The daytime sampling of melatonin may have limited the hormonal assessment. Further studies with nocturnal sampling are recommended.